Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Muneer Abidi, Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier:
NCT00293384
First received: February 16, 2006
Last updated: September 26, 2014
Last verified: September 2014
Results First Received: May 12, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Supportive Care
Conditions: Breast Cancer
Chronic Myeloproliferative Disorders
Gestational Trophoblastic Tumor
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Nausea and Vomiting
Neuroblastoma
Ovarian Cancer
Testicular Germ Cell Tumor
Interventions: Drug: Aprepitant
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Granisetron hydrochloride

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Aprepitant, Dexamethasone, Cytoxan & Kytril

Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.

Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.

Days 2 & 3: Aprepitant 80 mg once daily in the morning.

Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3

Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes

Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.

Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.


Participant Flow:   Overall Study
    Aprepitant, Dexamethasone, Cytoxan & Kytril  
STARTED     40  
COMPLETED     40  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Patients who received all doses of the study drug were considered evaluable patients.

Reporting Groups
  Description
Aprepitant, Dexamethasone, Cytoxan & Kytril

Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.

Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.

Days 2 & 3: Aprepitant 80 mg once daily in the morning.

Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3

Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes

Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.

Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.


Baseline Measures
    Aprepitant, Dexamethasone, Cytoxan & Kytril  
Number of Participants  
[units: participants]
  40  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     40  
>=65 years     0  
Gender  
[units: participants]
 
Female     17  
Male     23  
Region of Enrollment  
[units: participants]
 
United States     40  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Participants With Controlled Acute Vomiting   [ Time Frame: at 0-24 hours ]

2.  Secondary:   Delayed Vomiting Controlled   [ Time Frame: at 25-120 hours ]

3.  Secondary:   Toxicity Grade 3, 4, or 5   [ Time Frame: at 0-120 hours ]

4.  Other Pre-specified:   Overall Nausea Controlled   [ Time Frame: at 0-120 hours ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
There were no other significant limitations except for the details provided.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Muneer Abidi, M.D.
Organization: Barbara Ann Karmanos Cancer Institute
phone: (313) 576-8713
e-mail: abidim@karmanos.org


No publications provided


Responsible Party: Muneer Abidi, Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier: NCT00293384     History of Changes
Other Study ID Numbers: CDR0000456201, P30CA022453, WSU-D-2797, WSU-0504001728
Study First Received: February 16, 2006
Results First Received: May 12, 2014
Last Updated: September 26, 2014
Health Authority: United States: Federal Government
United States: Food and Drug Administration